Literature DB >> 18082716

The evidence of maternal microchimerism in biliary atresia using fluorescent in situ hybridization.

Makoto Hayashida1, Yuko Nishimoto, Toshiharu Matsuura, Yukiko Takahashi, Kenichi Kohashi, Ryota Souzaki, Tomoaki Taguchi.   

Abstract

BACKGROUND: Biliary atresia (BA) is a cholestatic disease of unknown etiology. It has recently been suggested that graft-vs-host disease caused by microchimerism is an etiology in the development of autoimmune disease. Moreover, the liver is a frequent target organ of graft-vs-host disease. The aim of this study is to identify the presence and extent of maternal microchimerism and to determine whether it plays a role in the etiology of BA.
METHODS: The liver biopsy specimens of 6 male patients with BA (BA group) and 6 males with other liver diseases (non-BA group) were assayed for X- and Y-chromosome using fluorescent in situ hybridization. The cells with 2 sex chromosomes in the nuclei were counted. Cells with 1 X- and 1 Y-chromosomes were considered to be host cells, and those with 2 X-chromosome were considered to be of maternal origin.
RESULTS: The frequency of cells with XX chromosomes per 1000 host cells in the BA group and the non-BA group were 3.00 +/- 0.75 and 0.99 +/- 0.50, respectively (P = .005). Moreover, the age at the time of biopsy did not affect the number of chimeric cells.
CONCLUSION: The presence of female cells in the liver of male patients with BA was significantly higher than in males with other liver disease. Maternal microchimerism is therefore suggested to contribute to the pathogenesis of BA.

Entities:  

Mesh:

Year:  2007        PMID: 18082716     DOI: 10.1016/j.jpedsurg.2007.08.039

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  15 in total

1.  Maternal microchimerism in patients with biliary atresia: Implications for allograft tolerance.

Authors:  Amar Nijagal; Shannon Fleck; Tippi C MacKenzie
Journal:  Chimerism       Date:  2012-04-01

Review 2.  Biliary atresia: will blocking inflammation tame the disease?

Authors:  Kazuhiko Bessho; Jorge A Bezerra
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

Review 3.  Pathogenesis of biliary atresia: defining biology to understand clinical phenotypes.

Authors:  Akihiro Asai; Alexander Miethke; Jorge A Bezerra
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-05-26       Impact factor: 46.802

Review 4.  Cirrhosis in children and adolescents: An overview.

Authors:  Raquel Borges Pinto; Ana Claudia Reis Schneider; Themis Reverbel da Silveira
Journal:  World J Hepatol       Date:  2015-03-27

Review 5.  Transfusion-associated microchimerism: the hybrid within.

Authors:  Evan M Bloch; Rachael P Jackman; Tzong-Hae Lee; Michael P Busch
Journal:  Transfus Med Rev       Date:  2012-10-24

Review 6.  Maternal microchimerism in biliary atresia: are maternal cells effector cells, targets, or just bystanders?

Authors:  Toshihiro Muraji
Journal:  Chimerism       Date:  2014-03-26

7.  Alterations in maternal-fetal cellular trafficking after fetal surgery.

Authors:  Payam Saadai; Tzong-Hae Lee; Geoanna Bautista; Kelly D Gonzales; Amar Nijagal; Michael P Busch; Chong Jai Kim; Roberto Romero; Hanmin Lee; Shinjiro Hirose; Larry Rand; Douglas Miniati; Diana L Farmer; Tippi C MacKenzie
Journal:  J Pediatr Surg       Date:  2012-06       Impact factor: 2.545

8.  Expression of programmed death-1 and its ligands in the liver of biliary atresia.

Authors:  Pan-Liang Wang; Jun Wang; Ying Zhou; Xiao-Song Chen; Ke-Jun Zhou; Jie Wen; Jian-Jun Zhang; Wei Cai
Journal:  World J Pediatr       Date:  2017-03-22       Impact factor: 2.764

Review 9.  Biliary atresia.

Authors:  Giorgina Mieli-Vergani; Diego Vergani
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

Review 10.  Unique manifestations of biliary atresia provide new immunological insight into its etiopathogenesis.

Authors:  Toshihiro Muraji; Haruo Ohtani; Satoshi Ieiri
Journal:  Pediatr Surg Int       Date:  2017-10-11       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.